Cardiology Pharmaceuticals
May 8, 2025
Marea Makes Progress on MAR001 May 8, 2025
Marea Therapeutics presented positive data from the Phase 2a clinical trial of its fat-targeting monoclonal antibody, MAR001, that could help address lipid and metabolic drivers of ASCVD. To assess MAR001’s impact on remnant cholesterol and triglycerides, researchers randomized 55 patients with hypertriglyceridemia to one of three doses (150, 300, and 450mg) or placebo and found… […]
Cardiology Pharmaceuticals
May 8, 2025
Obicetrapib Puts on a Show May 8, 2025
Results from NewAmsterdam Pharma’s Phase 3 BROADWAY and TANDEM trials suggest that obicetrapib could be an effective LDL-C lowering treatment, both on its own or combined with another drug. TANDEM examined the effects of a fixed-dose obicetrapib/ezetimibe combination therapy and found… BROADWAY put on a one-man show for obicetrapib as a monotherapy to help confirm […]
Surgeries & Interventions
May 5, 2025
FDA Approves TAVR for Asymptomatic AS May 5, 2025
TAVR will officially be an option for asymptomatic patients with severe aortic stenosis following the FDA’s approval of Edwards Lifesciences’ SAPIEN 3 platform for the patient group. EARLY TAVR was the first RCT designed to evaluate TAVR compared to watchful waiting for patients with asymptomatic severe AS. These results helped inform the FDA’s decision, but […]
Cardiology
May 1, 2025
Cardiac Wire’s Top Six of HRS 2025 May 1, 2025
Heart Rhythm Society and sunny San Diego brought together the biggest HRS in years, with everything from custom presentation theaters to exciting afterparties. We hope everyone who attended HRS 2025 had as much fun as we did, and we hope all of you enjoy these top-six takeaways from electrophysiology’s biggest weekend of the year. HRS […]
Atrial Fibrillation
April 28, 2025
GLP-1s Add AFib To Their Benefits List April 28, 2025
It seems like every week we’re discovering a new GLP-1 cardiac benefit, with the TRANSFORM-AF study now suggesting the drug could help reduce AFib burden. Examining the effects of GLP-1s on AFib, researchers examined 2.5k patients from 170 Veterans Affairs sites across the U.S. and found that AFib patients with obesity who were treated with […]
Surgeries & Interventions
April 24, 2025
RESILIA’s Eight Year Results Impress for SAVR April 24, 2025
Eight-year data presented at HVS 2025 suggests that SAVR valves that use Edwards Lifesciences’ RESILIA tissue have better long-term outcomes compared to non-RESILIA bioprosthetic SAVR valves. The eight year data is the longest follow-up for valve tissue technology to date and comes from 947 patients in the COMMENCE and MAGNA EASE studies who received SAVR […]
Artificial Intelligence
April 21, 2025
How AI is Expanding ECG and Echo’s Applications April 21, 2025
Building stronger evidence for AI’s place in cardiology, this week brought several examples of how AI can improve ECG use cases and automate Echo for new disease detection methods. Starting with AI improving ECG for coronary revascularization, a deep learning ECG model outperformed both clinician-led ECG and troponin T testing in predicting which ED patients […]
Cardiology Pharmaceuticals
April 17, 2025
Verve Vaults Forward From Topline Results April 17, 2025
Completing its pharma comeback story, Verve Therapeutics announced successful results from the Heart-2 Phase 1b Clinical Trial of its in-vivo base editing drug, VERVE-102, that targets the PCSK9 gene for reducing LDL-C. VERVE-102’s topline results come from a small group of 14 patients across three different dose cohorts (weight-based cohorts of 0.3, 0.45, and 0.6mg/kg) […]
Cardiology Pharmaceuticals
April 14, 2025
At Home Nasal Sprays and PSVT ER Visits April 14, 2025
Data analysis from the NODE-301 Phase 3 trial suggests that patients self-adminstering Milestone Pharmaceuticals’ etripamil (CARDAMYST) might be able to avoid ER visits for paroxysmal supraventricular tachycardia (PSVT). Sniffing around for proof of etripamil’s effectiveness, researchers analyzed data from parts 1 and 2 of the NODE-301 trial and found that patients who self-administered the drug […]
Cardiology Practices
April 10, 2025
Does Value Based Care Improve Cardiology? April 10, 2025
Casting doubt on value based cardiac care, a JAMA study found that outpatient cardiology practices enrolled in an accountable care organization (ACO) through the Medicare Shared Savings Program (MSSP) don’t offer better care than non-ACO practices. Evaluating the ACO incentives, researchers compared care quality data from the ACC’s NCDR PINNACLE Registry before and 6-12 months […]
Atrial Fibrillation
April 7, 2025
PFA or Cryoballoon for Paroxysmal AFib? April 7, 2025
Expanding the potential patient population for pulsed field ablation, results from the SINGLE SHOT CHAMPION study suggest PFA might be just as good as cryoballoon ablation for patients with paroxysmal AFib. In one of the first PFA versus cryoballoon head-to-heads, researchers randomized 210 patients with symptomatic paroxysmal AFib to undergo PFA with Boston Scientific’s Farapulse […]
Cardiology
April 3, 2025
The Top Trends of ACC.25 April 3, 2025
The ACC 2025 meeting is all wrapped up after matching the attendance and excitement of last year’s expo, with a clear trend toward better diagnostics and even better pharmaceuticals. Among dozens of highlights, here are Cardiac Wire’s seven biggest trends from ACC.25. The Takeaway From software and hardware innovations in the exhibit hall to strong […]